Amgen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma
Phase 3
Terminated
- Conditions
- Melanoma
- Interventions
- First Posted Date
- 2014-10-13
- Last Posted Date
- 2022-11-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 713
- Registration Number
- NCT02263508
- Locations
- 🇬🇧
Research Site, Southampton, United Kingdom
Evaluation of Two Epoetin Alfa Dosing Strategies in Subjects With Chronic Kidney Disease Receiving Hemodialysis
Phase 4
Completed
- Conditions
- Renal Insufficiency, ChronicAnemiaRenal DialysisErythrocyte Transfusion
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 216
- Registration Number
- NCT02253654
- Locations
- 🇵🇷
Research Site, Toa Baja, Puerto Rico
A Phase 1 Study of Oprozomib to Assess Food Effect, Drug-Drug Interaction With Midazolam, and Safety and Tolerability in Patients With Advanced Malignancies
Phase 1
Terminated
- Conditions
- Advanced Non-Central Nervous System (CNS) Malignancies
- Interventions
- First Posted Date
- 2014-09-18
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Amgen
- Target Recruit Count
- 43
- Registration Number
- NCT02244112
- Locations
- 🇺🇸
Mary Crowley Cancer Research Centers - Medical City, Dallas, Texas, United States
🇺🇸University of Texas MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Winship Cancer Institute, Atlanta, Georgia, United States
Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma
Phase 1
Withdrawn
- Conditions
- Advanced Hepatocellular Carcinoma
- Interventions
- First Posted Date
- 2014-08-28
- Last Posted Date
- 2017-05-02
- Lead Sponsor
- Amgen
- Registration Number
- NCT02227914
- Locations
- 🇺🇸
The University of Chicago Medical Center, Chicago, Illinois, United States
🇺🇸Lahey Hospital & Medical Center, Burlington, California, United States
🇺🇸The Ohio State University, Martha Morehouse Medical Plaza, Columbus, Ohio, United States
Clinical Trial to Evaluate Safety and Efficacy of CCX168 in ANCA-Associated Vasculitis
Phase 2
Completed
- Conditions
- ANCA-associated Vasculitis
- Interventions
- Drug: CCX168 10 mg, twice daily, plus cyclophosphamide/rituximab plus glucocorticoidsDrug: CCX168 30 mg, twice daily, cyclophosphamide/rituximab plus glucocorticoidsOther: Placebo, twice daily, plus cyclophosphamide/rituximab plus glucocorticoids
- First Posted Date
- 2014-08-21
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Amgen
- Target Recruit Count
- 42
- Registration Number
- NCT02222155
Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Melanoma
Phase 2
Completed
- Conditions
- Completely Resectable Stage IIIB, IIIC, or IVM1a Melanoma
- Interventions
- Procedure: Immediate surgical resection of melanoma lesion(s)
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2023-06-05
- Lead Sponsor
- Amgen
- Target Recruit Count
- 150
- Registration Number
- NCT02211131
- Locations
- 🇨🇭
Research Site, Zürich, Switzerland
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Phase 3
Completed
- Conditions
- Primary Hyperlipidemia and Mixed Dyslipidemia
- Interventions
- First Posted Date
- 2014-07-15
- Last Posted Date
- 2018-10-03
- Lead Sponsor
- Amgen
- Target Recruit Count
- 89
- Registration Number
- NCT02189837
- Locations
- 🇦🇺
Research Site, Nedlands, Western Australia, Australia
Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL
- Conditions
- Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Amgen
- Registration Number
- NCT02187354
- Locations
- 🇬🇧
Research Site, Sheffield, United Kingdom
Observational Study of Correction of Anaemia With Darbepoetin Alfa at QM Dosing Interval in Patients With CKD Not on Dialysis
Completed
- Conditions
- AnaemiaChronic Kidney Disease (CKD)
- First Posted Date
- 2014-07-10
- Last Posted Date
- 2016-03-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 308
- Registration Number
- NCT02185911
- Locations
- 🇪🇸
Research Site, Valencia, Comunidad Valenciana, Spain
Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy
Completed
- Conditions
- Chemotherapy-induced Febrile Neutropenia
- First Posted Date
- 2014-06-30
- Last Posted Date
- 2018-07-23
- Lead Sponsor
- Amgen
- Target Recruit Count
- 943
- Registration Number
- NCT02178475
- Locations
- 🇷🇴
Research Site, Ploiesti, Romania
© Copyright 2025. All Rights Reserved by MedPath